Multiple‐Dose Safety, Pharmacokinetics, and Pharmacodynamics of the μ‐Opioid Receptor Inverse Agonist GSK1521498
- 1 October 2012
- journal article
- research article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 52 (10) , 1456-1467
Abstract
The endogenous opioid system and μ‐opioid receptors in particular have been demonstrated to play a fundamental role in hedonic and motivational behaviors reinforced by rewards. In healthy participants, the authors examined the multiple‐dose safety, pharmacokinetic, and secondary pharmacodynamic profile of GSK1521498, a μ‐opioid receptor inverse agonist that is being developed for treatment of disorders of compulsive consumption. Clinically relevant doses of GSK1521498 (2, 5, and 10 mg) following once‐daily administration for 10 days, were well tolerated with no clinically relevant changes in vital signs, chemistry, or hematologic parameters and with a favorable neuropsychiatric profile. Following oral administration, median first time to reach maximum observed plasma concentration for GSK1521498 occurred 2 to 5 hours after dosing, with individual values ranging from 1 to 8 hours. Systemic exposure to GSK1521498 (area under the curve [0–∞] and maximum observed plasma concentration) increased in a slightly greater‐than‐dose‐proportional manner, and steady‐state plasma levels were reached within approximately 7 days. The secondary pharmacodynamic effects of GSK1521498 on cognition and pain threshold and tolerance were dose related, with mild to moderate impairments in measures of attention and reductions of pressure pain threshold and tolerance at the highest dose. These findings provide encouraging safety, tolerability, and pharmacokinetic data in support of the continued clinical development of GSK1521498.Keywords
This publication has 19 references indexed in Scilit:
- Pharmacological differentiation of opioid receptor antagonists by molecular and functional imaging of target occupancy and food reward-related brain activation in humansMolecular Psychiatry, 2011
- Opioid antagonists for alcohol dependenceCochrane Database of Systematic Reviews, 2010
- Hedonic and motivational roles of opioids in food reward: Implications for overeating disordersPharmacology Biochemistry and Behavior, 2010
- The endogenous opioid system: A common substrate in drug addictionDrug and Alcohol Dependence, 2010
- Reward Processing by the Opioid System in the BrainPhysiological Reviews, 2009
- From taste hedonics to motivational drive: central μ-opioid receptors and binge-eating behaviourInternational Journal of Neuropsychopharmacology, 2009
- Pressure pain thresholds of tender point sites in patients with fibromyalgia and in healthy controlsEuropean journal of pain, 2004
- Effects of sibutramine alone and with alcohol on cognitive function in healthy volunteersBritish Journal of Clinical Pharmacology, 2000
- Food reward: Brain substrates of wanting and likingNeuroscience & Biobehavioral Reviews, 1996
- Opioid-receptor mRNA expression in the rat CNS: anatomical and functional implicationsTrends in Neurosciences, 1995